Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | CMKLR1 | Q99788 | 8/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303237 | 0.90 | HTR3A (0.44) | HTR3ACYP4F2CYP4A11CMKLR1ATR | |
| SCHEMBL12429913 | 0.86 | HRH3 (0.35) | CYP4F2CYP4A11ATRCNR1CNR2 | |
| SCHEMBL177024 | 0.84 | CYP4F2 (0.43) | HTR3ACYP4F2CYP4A11CMKLR1ATR | |
| SCHEMBL176753 | 0.83 | CYP4F2 (0.44) | HTR3ACYP4F2CYP4A11CMKLR1ATR | |
| SCHEMBL2307876 | 0.81 | CYP4F2 (0.39) | HTR3ACYP4F2CYP4A11CMKLR1ATR | |
| SCHEMBL177022 | 0.81 | HTR3A (0.48) | HTR3ACYP4F2CYP4A11CMKLR1ATR | |
| SCHEMBL176881 | 0.81 | CYP4F2 (0.44) | HTR3ACYP4F2CYP4A11CMKLR1ATR | |
| SCHEMBL24013115 | 0.79 | CYP4F2 (0.47) | HTR3ACYP4F2CYP4A11ATRCNR1 | |
| SCHEMBL2237767 | 0.79 | HTR3A (0.46) | HTR3ACYP4F2CYP4A11CNR1CNR2 | |
| SCHEMBL176886 | 0.78 | FFAR1 (0.43) | HTR3ACYP4F2CYP4A11CMKLR1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351742-A1 | INDAZOLE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2011-08-03 | — | — | EP | claimed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | claimed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2351742-A1 | INDAZOLE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ADRB3, INSR, ADRB1 | HTR3A 37/4885CYP4F2 937/4885CYP4A11 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.